On this page of factors to consider before buying or selling Pfizer shares, we look at the key factors influencing the company's share price and performance. We analyse financial results, pharmaceutical innovations, strategic partnerships, regulatory developments and other relevant factors to help you make informed decisions. Whether you are a potential or current investor, this page will provide you with the information you need to understand buying or selling Pfizer shares.
First of all, you will need to keep an eye on any strategic agreements and partnerships that Pfizer may put in place with other companies or with competing groups in the pharmaceutical sector. Agreements concerning the research and development of new treatments are often positive for the growth of this group and its share price.
It is also important to keep an eye on the world's healthcare needs, with the most common diseases, or those on the increase, for which Pfizer could provide solutions.
Merger and acquisition operations completed abroad, notably in emerging markets are also good indicators of a rise in this asset price and should therefore be monitored.
It is also recommended to follow the launch of new products from the group and their success or failure following their entry onto the market that could generate increased sales or losses in income.
The regulations in effect relating to the sale of medicines are increasingly strict around the world and it is therefore important to monitor and take into account any changes in them.
Finally, as with numerous other activity sectors, that of the pharmaceutical industry continues to suffer from the effects of the European economic downtrend.
Pfizer Inc. is one of the world's largest pharmaceutical companies, playing a leading role in the discovery, development and marketing of innovative medicines to improve the health and well-being of people around the world. Founded in 1849, Pfizer is headquartered in New York, USA, and operates in more than 150 countries.
The company focuses on the research and development of medicines in a variety of therapeutic areas, including oncology, cardiovascular disease, vaccines, inflammatory diseases, neurological disorders and rare diseases.
Pfizer has been responsible for numerous medical discoveries and advances that have revolutionised the treatment of many conditions, saving millions of lives.
Pfizer's best-known medicines include Viagra for erectile dysfunction, Lipitor for lowering cholesterol, Celebrex for inflammatory pain, and Prevnar 13 for the prevention of pneumococcal disease in infants and adults.
In addition to its commitment to drug research and development, Pfizer has played a leading role in the fight against infectious diseases. The company has been a key player in the development of vaccines for diseases such as influenza, pneumonia, meningitis and, most recently, the COVID-19 vaccine in collaboration with BioNTech.
As a global pharmaceutical company, Pfizer is subject to strict regulations and rigorous oversight in every country where it operates. Drug safety is an absolute priority for the company.
Financially, Pfizer is listed on the New York Stock Exchange (NYSE) under the symbol "PFE". The company generates considerable revenue from the sale of its medicines and vaccines worldwide.
Photo credits: Montgomery County Planning Commission
The Pfizer group faces significant competition from several large pharmaceutical companies in the world that you should absolutely know about and of which here is a quick presentation:
First of all, the pharmaceutical group Novartis created in Switzerland in 1996 is a direct competitor of Pfizer. It was formed from the merger of Ciba-Geigy and Sandoz at that time and is currently headquartered in Basel.
This Swiss pharmaceutical company is also a serious competitor of Pfizer and one of the leading companies in the industry. It is active in both the pharmaceutical and diagnostic sectors and is present in more than 150 countries worldwide. Roche currently employs 94,000 people.
Of course, the French multinational giant Sanofi has activities that compete with Pfizer's, including pharmaceuticals and vaccines. It is one of the largest companies in this sector in terms of turnover and market capitalisation. The company is largely owned by the French group L'Oréal.
This other company, this time German, also specialises in the same field as Pfizer. It is a company that operates in the pharmaceutical field with its subsidiary Merck Serono and in the chemical field.
Another competitor of the Pfizer group is Gilead Sciences, an American pharmaceutical laboratory and one of the leaders in the sector.
Finally, Johnson & Johnson is an American pharmaceutical company founded in 1886, which mainly produces pharmaceutical and medical devices as well as hygiene products, cosmetics and related services for consumers and healthcare professionals. The company currently operates 250 subsidiaries in some 60 countries around the world and markets its products in more than 175 countries. The group is included in the Dow Jones stock index and J&J owns several brands of medicines and first aid supplies.
Of course, the Pfizer group does not only have enemies but also regularly sets up strategic partnerships with other companies as in the two examples we will mention here:
First and foremost and in 2020, the group of course collaborated with the company BioNTech in a cooperation to develop and distribute a vaccine against Covid-19, created using Messenger RNA technology. The agreement included a material transfer and collaboration agreement to enable the parties to start the cooperation quickly. Its objective was of course to accelerate the development of BioNTech's BNT162 vaccine candidate programme against the new mRNA-based coronavirus, the first in its therapeutic class. This was tested through clinical trials from April 2020 and the deal resulted in a fast and efficient collaboration. Recall that the two companies had already collaborated in 2018 in the development of a flu vaccine, again based on messenger RNA.
Also in 2020, the Pfizer group set up another strategic partnership, this time with the laboratory Myovant Sciences. The aim of this alliance was to jointly develop and market a pituitary gonatrophin-releasing hormone (GnRH) receptor antagonist under the name relugolix. This treatment is used in prostate cancer care and women's health in the US and Canada. Under the terms of the agreement, Myovant received an initial payment of $650 million in addition to several regulatory and commercial milestones, for a total amount of up to $4.2 billion. Pfizer has negotiated an exclusive right to market relogolix in oncology outside the US and Canada, excluding certain Asian countries.
To be able to analyse Pfizer's current and future share price performance, you need to know its major strengths and weaknesses. Here are the stock's major advantages and disadvantages:
Let's start by assessing the company's strengths, i.e. the factors that are most likely to boost its share price:
Let's now look at the company's weaknesses on the stock market, which could have a downward influence on its share price:
The Pfizer Company first came into being in 1849 in New York through the association between a German chemist, Charles Pfizer, and his cousin, a confectioner, Charles Erhart. In fact these two men first collaborated with the objective of creating and the large scale manufacturing of a type of confectionary named Santonine which was a remedy for treating intestinal worms but had a bitter taste. The associates had the idea of covering these pills with a nutty layer.
To successfully forecast the future trends in Pfizer shares you should complete two distinct types of analysis, the technical and fundamental analyses. For the first analysis you will use the volatility indicators and the online stock market chart trends. For the second you will need to follow all significant publications and events of this group and its activity sector.
Currently, Pfizer Group has several major private shareholders in its capital including The Vanguard Group with 7.74% of the shares, SSgA Funds Management with 5.20% of the shares, Capital Research & Management World Investors with 4.66%, Wellington Management Company with 4.51%, Capital Research & Management with 2.56%, BlackRock Fund Advisors with 2.42%, Putnam with .83%, Geode Capital Management with 1.61%, Northern Trust Investments with 1.24% and Norges Bank Investment Management with 1.07%.
You have several options for buying or selling Pfizer shares. You can choose to work with reputable online brokers who offer share trading services. Another option is to contact regulated brokers who offer online trading of CFDs or Contracts for Difference. If you prefer professional advice, a financial adviser can guide you through the process of buying or selling Pfizer shares. Before making a decision, compare fees, platform features and consider your risk tolerance. Also be sure to conduct your own research and make informed decisions.
eToro is a multi-asset platform which offers both investing in stocks and cryptoassets, as well as trading CFDs.
Please note that CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. {etoroCFDrisk}% of retail CFD accounts lose money. You should consider whether you can afford to take the high risk of losing your money.
Past performance is not an indication of future results. Trading history presented is less than 5 complete years and may not suffice as basis for investment decision.
Copy trading is a portfolio management service, provided by eToro (Europe) Ltd., which is authorised and regulated by the Cyprus Securities and Exchange Commission.
Cryptoasset investing is unregulated in some EU countries and the UK. No consumer protection. Your capital is at risk.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro.
